#Canada #Toronto #Specific Biologics #Dualase #Genome Canada

Specific Biologics and Western University's Collaborative Breakthrough

In an exciting initiative for the biotechnology sector, Specific Biologics Inc., a pioneering company in in vivo genome editing, has announced a significant collaboration with Western University. This partnership has been awarded a grant exceeding CAD$1.8 million from Genome Canada and Ontario Genomics through their Genomic Applications Partnership Program (GAPP). The primary objective of this funding is to develop a machine learning (ML) platform dedicated to enhancing the capabilities of the company's Dualase® genome editors.

This monumental grant will not only support the expansion of the Dualase® genome editing technologies but will also bring forth the potential to address various genetic diseases with high morbidity and mortality rates. The Dualase® platform is uniquely positioned as a leader in genome editing for its precision, efficiency, and programmability, making it a powerful tool in the treatment landscape for previously untreatable genetic disorders.

Development of a Pioneering Machine Learning Platform

The machine learning platform will be created alongside a research team led by Dr. David Edgell, a key figure in the discovery of Dualase® editors. This partnership builds on a long-standing collaborative relationship between Specific Biologics and Dr. Edgell's lab. The funding will enable the integration of vast genomic datasets with structural modeling and experimental data, paving the way for developing predictive algorithms aimed at swiftly identifying effective Dualase® editors for new therapeutic targets.

One of the most notable aspects of the Dualase® technology is its ability to precisely collapse toxic DNA repeat expansions without off-target effects, thus offering a novel approach to addressing diseases such as C9ORF72 amyotrophic lateral sclerosis (ALS), which is recognized as the leading genetic cause of ALS with no available disease-modifying therapies. The integration of a machine learning tool is expected to significantly accelerate the development process of therapeutic candidates not only for ALS but also for other genetic conditions, including Huntington's Disease.

Remarks from Key Stakeholders

Dr. Brent Stead, the CEO of Specific Biologics, commented on the development, noting, "This funding supports a natural evolution of the Dualase® platform... By integrating machine learning into our development pipeline, we aim to dramatically accelerate the discovery of proprietary Dualase® editors as precision genetic medicines."

In addition, Dr. Edgell expressed optimism about the partnership, stating, "Machine learning can be a powerful tool in genome engineering... This program will allow us to integrate computational prediction with experimental validation to rapidly identify editors with optimal characteristics."

The Future of Genome Editing

Specific Biologics is revolutionizing the biotechnology landscape with its Dualase® technology, aimed at precise and efficient genome editing in vivo. The grant from Genome Canada and Ontario Genomics represents a significant step forward, enabling the company to accelerate its research into therapeutic solutions that could transform the lives of patients with severe genetic disorders.

With the focus on innovating and development, Specific Biologics stands at the forefront of genetic medicine, combining cutting-edge technology with collaborative efforts to push the boundaries of what is possible in medical science. The long-term implications of these advancements could lead to a new era of therapeutic strategies that offer hope to patients suffering from previously untreatable illnesses.

For more information about Specific Biologics and their groundbreaking work, visit Specific Biologics or follow them on LinkedIn.